ESULAB_Review.png

• nearly 200 participants
• from 23 countries
• 30 posters
• 28 talks

Picture: ©Lanzatech

Fossil carbon is in nearly everything we use in our daily lives ranging from power and fuels to fibers, coatings, and materials used in our clothes, packaging, toys, and household goods. Virgin fossil carbon use in these products is not sustainable given the current understanding of the impact of extracted, emitted, and waste carbon on our environment, climate, and vulnerable populations.

Agonists of the innate immune system might turn cold to hot (inflamed) tumours. © Dana Farber Cancer Center

Kupando has raised €13m in Series A financing co-led by Remiges Ventures and LifeCare Partners to initiate clinical development of KUP101.

Inflamed joint © Laboratoires Servier

Danish AI health app developer DAMAN P/S has entered the €12m EU-funded Squeeze project, that aims to find stratification biomarkers for DMARDs in rheumatoid arthritis (RA).

Picture: © Thermo Fisher Scientific

The technological and pharmacological advances lead to an increase in the ­number of molecules for R&D that are challenging and difficult to manufacture. To improve ­clinical success, pharma and biotech companies are seeking innovative ways to accelerate progress and ­reduce scientific, economic, and delivery risks.

© pixabay.com

Quinten Group’s French healthcare arm Quinten Health has closed a financing round to advance disease modeling platforms and virtual twins in real-world.

© Bavarian Nordic

Bavarian Nordic A/S has expand its smallpox contract signed with the Canadian PHAC in June from $56m to $470m including $180m in contract options.

Picture: Mimetas

Leiden-based Mimetas, specialist in organ-on-chip-based disease models for drug discovery and development, has appointed Dhaval Patel (UCB, Belgium) as Chair of its Board of Directors.

Thumbnail_Thermo_3.png

Why are so many vaccine developers choosing Thermo Scientific Charged Aerosol Detection (CAD)? Hear the third very good reasons why CAD was used for analysis of lipid nanoparticles in approved mRNA vaccines.

Genfit's headquarters in Lille. © Genfit SA

Through the acquisition of Versantis for €40m upfront and further €65m in milestones, Genfit SA has added three clinical and preclinical candidates to its liver drug portfolio.